远大医药TLX591-CDx新药上市申请获国家药监局受理

Core Viewpoint - YuanDa Pharmaceutical has submitted a new drug application for TLX591-CDx, a novel radiopharmaceutical for diagnosing prostate cancer, to the National Medical Products Administration of China, which has been accepted [1] Group 1: Company Developments - TLX591-CDx is a globally innovative diagnostic radiopharmaceutical based on radiolabeled small molecule conjugate technology [1] - The drug targets prostate-specific membrane antigen and is suitable for diagnosing both newly diagnosed and recurrent prostate cancer [1]